IGC Pharma, Inc. (NASDAQ:IGC) | WebDisclosure

Basculer en Français

11289	Companies
250812	Keywords
179542	Articles
136601	Press releases

Home
Companies
IGC Pharma, Inc.

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 11 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 11 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 11 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 11 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 2 years ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 2 years ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 2 years ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 2 years 1 month ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 2 years 1 month ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 2 years 1 month ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Accesswire

Published on 11/05/2026 at 15:20, 28 minutes ago

MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 1 hour 17 minutes ago

First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 1 hour 23 minutes ago

Polaris Renewable Energy Announces Q3 2026 Results
Published on 11/05/2026 at 14:20, 1 hour 28 minutes ago

Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 33 minutes ago

Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 15:34, 13 minutes ago

Finexity AG: NuWays and GBC confirm price targets following Capital Markets Day and 9-month figures, taking the share split into account
Published on 11/05/2026 at 15:10, 38 minutes ago

Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 49 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/05/2026 at 14:58, 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 14:57, 51 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc

Les Echos

Published on 11/05/2026 at 15:01, 47 minutes ago

Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 32 minutes ago

Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 32 minutes ago

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
Published on 11/05/2026 at 07:44, 8 hours 3 minutes ago

Résultats d’ENGIE 9 mois 2026
Published on 11/05/2026 at 07:44, 8 hours 3 minutes ago

ENGIE 9M 2026 results

View all LES ECHOS COMFI WIRE